Literature DB >> 2465016

Chemotherapy-radiation interactions in human cervix carcinoma xenografts.

K S Tonkin1, L R Kelland, G G Steel.   

Abstract

The combination of irradiation and four agents of clinical interest in the treatment of cervix carcinoma (bleomycin, etoposide, cisplatin and ifosfamide) have been investigated using two human cervix carcinoma xenografts in nude mice. As a model of clinical brachytherapy regimes, radiation was administered at a continuous low dose rate of 5 cGy min-1 to a total dose of 9 or 12 Gy. No substantial enhancement in tumour growth delay over that observed for radiation alone was observed with bleomycin, etoposide or cisplatin. Ifosfamide, however, led to substantial additional growth delay, an effect which was lost when irradiation was administered at a higher dose rate of 70 cGy min-1. As dose-rates of around 5 cGy min-1 allow greater repair of radiation damage than at the higher dose-rate without significant cell cycling or repopulation, it is possible that ifosfamide may act as an inhibitor of repair processes in this model. It would be of interest to evaluate the role of ifosfamide and brachytherapy regimes in the clinical treatment of carcinoma of the cervix.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2465016      PMCID: PMC2246868          DOI: 10.1038/bjc.1988.300

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

1.  Characterization of four new cell lines derived from human squamous carcinomas of the uterine cervix.

Authors:  L R Kelland; L Burgess; G G Steel
Journal:  Cancer Res       Date:  1987-09-15       Impact factor: 12.701

2.  Occult advanced cervical cancer.

Authors:  B G Ward; J H Shepherd; J M Monaghan
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-04

Review 3.  Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancer.

Authors:  I F Tannock; G Browman
Journal:  J Clin Oncol       Date:  1986-07       Impact factor: 44.544

4.  Combined chemotherapy, radiation, and surgery for epithelial cancer of the anal canal.

Authors:  W R Meeker; B J Sickle-Santanello; G Philpott; D Kenady; K I Bland; G H Hill; M B Popp
Journal:  Cancer       Date:  1986-02-01       Impact factor: 6.860

5.  Results and toxicity of the treatment of anal canal carcinoma by radiation therapy or radiation therapy and chemotherapy.

Authors:  B Cummings; T Keane; G Thomas; A Harwood; W Rider
Journal:  Cancer       Date:  1984-11-15       Impact factor: 6.860

6.  Treatment of advanced squamous cell carcinoma of the cervix with cis-platinum (II) diamminedichloride (NSC-119875).

Authors:  C J Cohen; G Deppe; C A Castro-Marin; H W Bruckner
Journal:  Am J Obstet Gynecol       Date:  1978-04-01       Impact factor: 8.661

7.  cis-Dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group.

Authors:  T Thigpen; H Shingleton; H Homesley; L LaGasse; J Blessing
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

8.  Dose-rate effects and the repair of radiation damage.

Authors:  G G Steel; J D Down; J H Peacock; T C Stephens
Journal:  Radiother Oncol       Date:  1986-04       Impact factor: 6.280

9.  The effect of low dose-rate and cyclophosphamide on the radiation tolerance of the mouse lung.

Authors:  S P Lockhart; J D Down; G G Steel
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-08       Impact factor: 7.038

10.  Combined radiotherapy and chemotherapy for advanced carcinoma of the cervix.

Authors:  P R Blake; A N Branson; H E Lambert
Journal:  Clin Radiol       Date:  1986-09       Impact factor: 2.350

View more
  2 in total

Review 1.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model.

Authors:  Carla Hajj; James Russell; Charles P Hart; Karyn A Goodman; Maeve A Lowery; Adriana Haimovitz-Friedman; Joseph O Deasy; John L Humm
Journal:  Transl Oncol       Date:  2017-07-31       Impact factor: 4.243

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.